{
    "PTIX": {
        "short_name": "Protagenic Therapeutics, Inc.",
        "long_name": "Protagenic Therapeutics, Inc.",
        "summary": "Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Technology",
        "industry": "Networking & Communication Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "state": "NY",
        "city": "New York",
        "zipcode": "10010",
        "website": "http://www.protagenic.com",
        "market_cap": 28903880
    }
}